Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.00p -2.05% 47.75p 47.00p 48.50p 48.75p 47.75p 48.75p 91,173 15:29:57
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 0.5 -7.4 -8.7 - 55.91

Angle Share Discussion Threads

Showing 47876 to 47898 of 47900 messages
Chat Pages: 1916  1915  1914  1913  1912  1911  1910  1909  1908  1907  1906  1905  Older
DateSubjectAuthorDiscuss
20/2/2018
15:46
Thanks Waterloo- good to see AGL mentioned with the big boys.
semper vigilans
20/2/2018
15:42
htTp://menafn.com/1096482821/Liquid-Biopsy-Paving-the-Way-to-Growth-through-Strategic-Transactions
waterloo01
16/2/2018
19:05
Yes see them 4legs. Delayed from this morning. Didn't budge the share price but still good to see.
maxie23
16/2/2018
18:28
Nice to see a couple of buys (325,000 and 314,211 vol)
4legs
15/2/2018
14:59
Topped up. Full holding bought back now. Will stick and see what happens.
bagpuss67
14/2/2018
09:02
Yes hope all ok with him. It would be easier as he did a good job of it. Quite a few of the regulars haven't been on here for quite sometime. Hopefully just taking a breather from the board (and the duff share price as you say).
maxie23
14/2/2018
08:53
Maybe Maxie - just thought it easier for SK to do it. Hope all is well with him aside from the duff share price here!
semper vigilans
14/2/2018
08:47
SV just hoping that SK is still invested here. There's alot of news to be updated on the thread. If not is a new thread the only option?
maxie23
12/2/2018
18:02
SV - if ADRs are anything like VAVs there is a good chance they will be nibbled!
chippyfriday
12/2/2018
14:13
SK - sorry to be a pain, but would it please be possible to bring the header up to date?
semper vigilans
12/2/2018
13:26
I am really surprised at the lack of share purches from our friends over the water. Not enough PR going on. A US listing would really catapult the current share price
lairddavid
12/2/2018
13:23
I wonder if, after the Abbott arrangement, the ADRs may get nibbled?
semper vigilans
11/2/2018
11:59
Don’t know if anyone has posted this yet but hopefully it will generate some interest. Presumably it will be summary of key points potential investors should know htTPS://www.sharesmagazine.co.uk/events/event/shares-investor-evening-manchester-200218
chippyfriday
10/2/2018
22:05
Copied from lse site Breast cancer trial has now appeared on the Clinical Trials Register. Start date is Feb, so any day now and primary completion date is June. It seems to have been a long time coming and good to see it finally there in black and white. hxxps://clinicaltrials.gov/ct2/show/NCT03427450?term=parsortix&rank=1
aja5
10/2/2018
20:36
Thanks Maxie Looking at the programme Angle have a 20 min slot at 15:10 on 15/2, presented by Eva Obermayr, Post-Doctoral Scientist, Department of Obstetrics and Gynecology; Medical University of Vienna, Austria Molecular Detection Of Circulating Tumor Cells Enriched By The ParsortixTM Technology • We evaluated the novel ParsortixTM technology for molecular detection of rare cells • The ParsortixTM technology achieves an efficient leukocyte depletion and enables high qPCR specificity • The approach was further evaluated in patient samples to detect CTCs
miavoce
10/2/2018
20:16
Both Angle and Qiagen are sponsors at this event in Manchester next week. I'm sure Angle may well be presenting too. HTTPS://www.biomarkers-congress.com
maxie23
10/2/2018
17:37
Thanks for heads up Boom ..great news RNS next week and now the count down to FDA approval can truly start
life guard
10/2/2018
17:26
Thanks Bermuda.
miavoce
10/2/2018
16:18
Thanks Bermuda. It would be good to get a mention in a Sunday paper.
semper vigilans
10/2/2018
15:52
Excellent news and guess the Abbott tie up seems even more important. The selection criteria below is as wide a selection as you can get. They are going for a broad approval rather than only in certain stages of the cancer. MBC Patients (Cancers) Women with either newly diagnosed metastatic breast cancer who are about to start a new line of therapy of any type for the treatment and/or management of their disease or those with currently progressive or recurrent disease (as determined by any means) will be eligible for enrolment into the cancer population. All eligible and consenting subjects will have blood draw. Edit: It also strikes me that assuming they continue to match what they have demonstrated so far, one interesting outcome will also be the number of the 200 healthy volunteers where they find some CTC;s. That's where it starts getting considered for even wider use in detection pre any diagnosis and the potential power of liquid biopsy. Still 1st things 1st!
waterloo01
10/2/2018
15:43
Breast cancer trial has now appeared on the Clinical Trials Register. Start date is Feb, so any day now and primary completion date is June. It seems to have been a long time coming and good to see it finally there in black and white. hTTps://clinicaltrials.gov/ct2/show/NCT03427450?term=parsortix&rank=1
bermudashorts
08/2/2018
19:51
It makes good reading - Discover how partnerships with Abbott Molecular can lead to global access.personalized-partnership.jpg Some of the world's leading pharmaceutical, biological, and entrepreneurial companies have selected Abbott Molecular as their partner to develop and commercialize comprehensive, companion diagnostic products and strategies. Our teams of scientists and engineers, along with experts in legal, health economic and outcomes research, medical affairs, clinical affairs, regulatory affairs, and marketing are dedicated to ensuring successful collaborations. Abbott's global regulatory infrastructure supports products in more than 130 countries. This broad portfolio has provided the experience necessary to guide discussions with regulatory agencies and design effective global clinical trials. These activities support the EU CE mark, FDA 510(k) clearance, and FDA PMA, Japan PMDA, and other approval processes. We are investigating new biomarkers in oncology and other therapeutic areas. Learn more about our solutions pipline >> To discuss a potential partnership, please contact us >> Technology-Icon.png Technology and Platform Capabilities
chippyfriday
08/2/2018
17:38
htTps://www.abbottcdx.com/pharmaceutical-partners.html
mikepompeyfan
Chat Pages: 1916  1915  1914  1913  1912  1911  1910  1909  1908  1907  1906  1905  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20180222 04:40:09